LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway

Sui,Xiaomei; Sui,Yana; Wang,Yonghui

doi:10.3892/mmr.2018.8856

LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway

Authors:
- Xiaomei Sui
- Yana Sui
- Yonghui Wang
View Affiliations

Affiliations: Department of Radiotherapy, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261041, P.R. China, Department of Emergency, Weifang Traditional Chinese Hospital, Weifang, Shandong 261041, P.R. China, Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: April 5, 2018 https://doi.org/10.3892/mmr.2018.8856
Pages: 7521-7528
Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of thyroid cancer has increased the past few decades, the most frequent type has been identified to be the papillary thyroid carcinoma (PTC). Following thyroidectomy, radioiodine ablation treatment on PTC is routinely performed. However, many patients do not benefit from radioiodine therapy. Therefore, novel targeted therapies to suppress tumor growth and improve radioiodine uptake are required. La ribonucleoprotein domain family member (LARP)7 is a member of the LARP family and functions as a potential suppressor of the progression of carcinoma. In the present study, the expression status of LARP7 in PTC tissues and cell lines was investigated, and the cell viability, proliferation and apoptotic rate, radioiodine uptake ability of PTC cells with overexpression of LARP7 in vitro was determined. Expression levels of LARP7 were significantly downregulated in PTC tissues and cell lines. Overexpression of LARP7 inhibited the proliferation and increased the radioiodine uptake ability of PTC cells in vitro and inhibited the tumor growth in vivo. Furthermore, LARP7 overexpression inhibited the sonic hedgehog (SHH) signaling pathway and increased sodium/iodide symporter (NIS) expression. However, treatment with recombinant human SHH partially reduced radioiodine uptake ability and NIS expression induced by LARP7. In conclusion, LARP7 may act as a tumor suppressor in PTC by inhibiting the SHH signaling pathway and may be a promising therapeutic target in patients with PTC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Lopes JP and Fonseca E: BRAF gene mutation in the natural history of papillary thyroid carcinoma: Diagnostic and prognostic implications. Acta Med Port. 24 Suppl 4:S855–S868. 2011.(In Portuguese).
3	Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lupoli R, Cacciapuoti M, Tortora A, Barba L, Verde N, Romano F, Vastarella M, Fonderico F, Masone S, Milone M, et al: Clinical outcome in differentiated thyroid carcinoma and microcarcinoma. Int J Surg. 12 Suppl 1:S148–S151. 2014. View Article : Google Scholar : PubMed/NCBI
5	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ji X, Lu H, Zhou Q and Luo K: LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. Elife. 3:e029072014. View Article : Google Scholar : PubMed/NCBI
7	Cheng Y, Jin Z, Agarwal R, Ma K, Yang J, Ibrahim S, Olaru AV, David S, Ashktorab H, Smoot DT, et al: LARP7 is a potential tumor suppressor gene in gastric cancer. Lab Invest. 92:1013–1019. 2012. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Wang YH, Sui YN, Yan K, Wang LS, Wang F and Zhou JH: BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Oncol Rep. 33:1699–1706. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kondo T, Asa SL and Ezzat S: Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am. 37(389–400): ix2008.
11	Schlumberger M and Sherman SI: Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 166:5–11. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sherman SI: Targeted therapies for thyroid tumors. Mod Pathol. 24 Suppl 2:S44–S52. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kogai T and Brent GA: The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 135:355–370. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chung JK and Cheon GJ: Radioiodine therapy in differentiated thyroid cancer: The first targeted therapy in oncology. Endocrinol Metab (Seoul). 29:233–239. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ma S, Wang Q, Ma X, Wu L, Guo F, Ji H, Liu F, Zhao Y and Qin G: FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway. Tumour Biol. 37:989–998. 2016. View Article : Google Scholar : PubMed/NCBI
16	Xiang C, Zhang ML, Zhao QZ, Xie QP, Yan HC, Yu X, Wang P and Wang Y: LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget. 8:22954–22967. 2017. View Article : Google Scholar : PubMed/NCBI
17	Bayfield MA, Yang R and Maraia RJ: Conserved and divergent features of the structure and function of La and La-related proteins (LARPs). Biochim Biophys Acta. 1799:365–378. 2010. View Article : Google Scholar : PubMed/NCBI
18	Barboric M, Lenasi T, Chen H, Johansen EB, Guo S and Peterlin BM: 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc Natl Acad Sci USA. 106:7798–7803. 2009. View Article : Google Scholar : PubMed/NCBI
19	Swarbreck D, Wilks C, Lamesch P, Berardini TZ, Garcia-Hernandez M, Foerster H, Li D, Meyer T, Muller R, Ploetz L, et al: The arabidopsis information resource (TAIR): Gene structure and function annotation. Nucleic Acids Res. 36:(Database Issue). D1009–D1014. 2008. View Article : Google Scholar : PubMed/NCBI
20	Bres V, Yoh SM and Jones KA: The multi-tasking P-TEFb complex. Curr Opin Cell Biol. 20:334–340. 2008. View Article : Google Scholar : PubMed/NCBI
21	Williamson AJ, Doscas ME, Ye J, Heiden KB, Xing M, Li Y, Prinz RA and Xu X: The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met. Oncotarget. 7:10472–10485. 2016. View Article : Google Scholar : PubMed/NCBI
22	Xu X, Ding H, Rao G, Arora S, Saclarides CP, Esparaz J, Gattuso P, Solorzano CC and Prinz RA: Activation of the sonic hedgehog pathway in thyroid neoplasms and its potential role in tumor cell proliferation. Endocr Relat Cancer. 19:167–179. 2012. View Article : Google Scholar : PubMed/NCBI
23	Heiden KB, Williamson AJ, Doscas ME, Ye J, Wang Y, Liu D, Xing M, Prinz RA and Xu X: The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab. 99:E2178–E2187. 2014. View Article : Google Scholar : PubMed/NCBI
24	Rimkus TK, Carpenter RL, Qasem S, Chan M and Lo HW: Targeting the sonic hedgehog signaling pathway: Review of smoothened and GLI inhibitors. Cancers (Basel). 8:E222016. View Article : Google Scholar : PubMed/NCBI